Compare
CNS Pharmaceuticals, Inc. vs GRI Bio, Inc. vs Palatin Technologies Inc vs IGC Pharma, Inc.
| Latest fiscal year | CNS Pharmaceuticals, Inc. CNSP | GRI Bio, Inc. GRI | Palatin Technologies Inc PTN | IGC Pharma, Inc. IGCLast annual report: year ended 2025-03-31 |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-03-31 |
| Revenue | n/a | n/a | $13.19M | $1.27M |
| Revenue growth (YoY) | n/a | n/a | n/a | -5.5% |
| Gross margin | n/a | n/a | n/a | 48.7% |
| Operating margin | n/a | n/a | -65.7% | -585.8% |
| Net margin | n/a | n/a | -63.5% | -560.3% |
| Net income | -$15.85M | -$11.96M | -$8.38M | -$7.12M |
| EPS (Diluted) | -$35.75 | -$121.80 | -$2.96 | -$0.09 |
| Operating cash flow | -$13.81M | -$10.19M | -$13.53M | -$4.79M |
| Free cash flow | -$13.83M | -$10.19M | -$13.58M | -$4.91M |
| Cash & equivalents | $7.20M | $8.23M | $7.49M | $405.0K |
| Total assets | $8.62M | $8.67M | $8.52M | $8.75M |
| Total liabilities | $4.10M | $2.66M | $1.84M | $2.42M |
| Shareholders' equity | $4.52M | $6.01M | $6.69M | $6.33M |
| Return on year-end equity | -350.5% | -199.0% | -125.3% | -112.5% |
| Shares outstanding | 632.5K | 497.7K | 1.78M | 80.88M |
Revenue, most recent five fiscal years
| Fiscal year | CNS Pharmaceuticals, Inc. | GRI Bio, Inc. | Palatin Technologies Inc | IGC Pharma, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2021-12-31 | $13.19M Ended 2026-06-30 | $1.27M Ended 2025-03-31 |
| 1 year earlier | n/a | $100.0K Ended 2020-12-31 | n/a | $1.34M Ended 2024-03-31 |
| 2 years earlier | n/a | n/a | n/a | $911.0K Ended 2023-03-31 |
| 3 years earlier | n/a | n/a | n/a | $397.0K Ended 2022-03-31 |
| 4 years earlier | n/a | n/a | n/a | $898.0K Ended 2021-03-31 |